Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uniparental Disomy | 9 | 2023 | 63 | 3.580 |
Why?
|
Isochromosomes | 1 | 2022 | 55 | 0.780 |
Why?
|
WT1 Proteins | 3 | 2013 | 107 | 0.710 |
Why?
|
Papillomavirus Infections | 2 | 2019 | 999 | 0.660 |
Why?
|
Genome-Wide Association Study | 5 | 2019 | 2348 | 0.630 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 3656 | 0.590 |
Why?
|
Human Papillomavirus DNA Tests | 1 | 2017 | 16 | 0.570 |
Why?
|
Alleles | 2 | 2022 | 2590 | 0.530 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2017 | 2354 | 0.510 |
Why?
|
Alcohol Drinking | 1 | 2019 | 600 | 0.500 |
Why?
|
DNA, Viral | 1 | 2017 | 756 | 0.470 |
Why?
|
Genes, Wilms Tumor | 1 | 2013 | 62 | 0.440 |
Why?
|
Papillomaviridae | 1 | 2017 | 636 | 0.440 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2013 | 157 | 0.420 |
Why?
|
Neoplasms | 5 | 2022 | 15900 | 0.420 |
Why?
|
Inheritance Patterns | 1 | 2012 | 136 | 0.410 |
Why?
|
Receptor, ErbB-2 | 4 | 2013 | 2650 | 0.380 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4784 | 0.380 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 806 | 0.370 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 632 | 0.360 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2015 | 496 | 0.360 |
Why?
|
Biomarkers, Tumor | 3 | 2017 | 10699 | 0.360 |
Why?
|
Homozygote | 3 | 2023 | 772 | 0.350 |
Why?
|
Smoking | 1 | 2019 | 2550 | 0.330 |
Why?
|
Neoplasm Grading | 3 | 2019 | 1822 | 0.320 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2023 | 5587 | 0.290 |
Why?
|
Genome, Human | 2 | 2012 | 1885 | 0.280 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2019 | 4646 | 0.280 |
Why?
|
Breast Neoplasms | 6 | 2013 | 16182 | 0.280 |
Why?
|
Genomics | 2 | 2019 | 2834 | 0.270 |
Why?
|
Databases, Genetic | 2 | 2019 | 757 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5566 | 0.260 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 2573 | 0.240 |
Why?
|
Receptors, Progesterone | 1 | 2010 | 1603 | 0.240 |
Why?
|
Mutation | 5 | 2019 | 15901 | 0.230 |
Why?
|
Prognosis | 6 | 2019 | 22466 | 0.220 |
Why?
|
Receptors, Estrogen | 1 | 2010 | 2159 | 0.220 |
Why?
|
MicroRNAs | 1 | 2015 | 2886 | 0.210 |
Why?
|
Gene Expression Profiling | 4 | 2019 | 5141 | 0.200 |
Why?
|
Sarcoma | 1 | 2012 | 1836 | 0.200 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 4961 | 0.190 |
Why?
|
Neoplasm Staging | 4 | 2019 | 14003 | 0.190 |
Why?
|
Lung Neoplasms | 1 | 2023 | 12020 | 0.180 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2017 | 9036 | 0.180 |
Why?
|
Sequence Deletion | 1 | 2023 | 909 | 0.180 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2015 | 668 | 0.170 |
Why?
|
Epigenesis, Genetic | 2 | 2017 | 1442 | 0.160 |
Why?
|
Loss of Function Mutation | 1 | 2019 | 165 | 0.160 |
Why?
|
Humans | 17 | 2023 | 270462 | 0.160 |
Why?
|
Gain of Function Mutation | 1 | 2019 | 133 | 0.160 |
Why?
|
Virus Integration | 1 | 2017 | 73 | 0.140 |
Why?
|
Cell Transformation, Viral | 1 | 2017 | 174 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6253 | 0.130 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2017 | 197 | 0.130 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2012 | 2474 | 0.130 |
Why?
|
Host-Pathogen Interactions | 1 | 2017 | 304 | 0.120 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2015 | 183 | 0.120 |
Why?
|
Datasets as Topic | 1 | 2015 | 179 | 0.120 |
Why?
|
Epigenomics | 1 | 2015 | 273 | 0.120 |
Why?
|
RNA Isoforms | 1 | 2013 | 8 | 0.120 |
Why?
|
Female | 9 | 2019 | 148723 | 0.110 |
Why?
|
Centromere | 1 | 2012 | 139 | 0.100 |
Why?
|
Lung | 1 | 2023 | 3294 | 0.100 |
Why?
|
MCF-7 Cells | 1 | 2013 | 547 | 0.100 |
Why?
|
Chromosomes, Human | 1 | 2012 | 288 | 0.100 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2011 | 149 | 0.090 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 5099 | 0.090 |
Why?
|
Middle Aged | 4 | 2019 | 90192 | 0.080 |
Why?
|
Telomere | 1 | 2012 | 549 | 0.080 |
Why?
|
Blotting, Western | 2 | 2013 | 3586 | 0.080 |
Why?
|
Chromosome Deletion | 1 | 2012 | 1049 | 0.080 |
Why?
|
Regression Analysis | 1 | 2011 | 1571 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2019 | 10258 | 0.070 |
Why?
|
Up-Regulation | 1 | 2013 | 2421 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3603 | 0.070 |
Why?
|
Loss of Heterozygosity | 1 | 2009 | 622 | 0.070 |
Why?
|
Translocation, Genetic | 1 | 2012 | 1285 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2012 | 2357 | 0.070 |
Why?
|
Chromosome Disorders | 1 | 2009 | 423 | 0.070 |
Why?
|
Computational Biology | 1 | 2012 | 1293 | 0.070 |
Why?
|
Survival Rate | 1 | 2019 | 12509 | 0.070 |
Why?
|
Aged | 3 | 2019 | 73248 | 0.060 |
Why?
|
Cyclin D | 1 | 2005 | 39 | 0.060 |
Why?
|
Adult | 3 | 2019 | 81851 | 0.060 |
Why?
|
Precision Medicine | 1 | 2012 | 1207 | 0.060 |
Why?
|
S Phase | 1 | 2005 | 288 | 0.060 |
Why?
|
Genetic Testing | 1 | 2012 | 1697 | 0.060 |
Why?
|
Fenretinide | 1 | 2004 | 100 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2013 | 6397 | 0.060 |
Why?
|
Cell Division | 2 | 2005 | 2657 | 0.050 |
Why?
|
Cyclins | 1 | 2005 | 467 | 0.050 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 231 | 0.050 |
Why?
|
Isoenzymes | 1 | 2004 | 651 | 0.050 |
Why?
|
Phenotype | 1 | 2012 | 6503 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2015 | 5403 | 0.050 |
Why?
|
Apoptosis | 2 | 2005 | 7752 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 5775 | 0.040 |
Why?
|
Signal Transduction | 1 | 2017 | 12098 | 0.040 |
Why?
|
Male | 2 | 2019 | 128209 | 0.040 |
Why?
|
Down-Regulation | 1 | 2002 | 2091 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2005 | 14825 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2011 | 30976 | 0.020 |
Why?
|
Animals | 1 | 2012 | 62012 | 0.020 |
Why?
|
Nitrobenzenes | 1 | 2004 | 32 | 0.010 |
Why?
|
Dinoprost | 1 | 2004 | 36 | 0.010 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2004 | 177 | 0.010 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2004 | 198 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 495 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 2002 | 255 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2004 | 14614 | 0.010 |
Why?
|
Liposomes | 1 | 2002 | 705 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2004 | 659 | 0.010 |
Why?
|
Estradiol | 1 | 2002 | 828 | 0.010 |
Why?
|
Tamoxifen | 1 | 2002 | 875 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2002 | 841 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2004 | 2073 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 5759 | 0.010 |
Why?
|
Cell Line | 1 | 2002 | 5339 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2004 | 2616 | 0.010 |
Why?
|
Sulfonamides | 1 | 2004 | 1933 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2004 | 2929 | 0.010 |
Why?
|